A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb7195

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb7195

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs XmAb 7195 (Primary)
  • Indications Allergic asthma; Allergic conjunctivitis; Allergic rhinitis; Atopic dermatitis; Hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors Xencor
  • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 28 Jun 2016 According to a Xencor media release, the company will discuss data from this trial at its Analyst Day on 28 June 2016.
    • 18 May 2016 Results (part I, n = 40) presented at the 112th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top